Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial - Calabresi, P A; Radue, E W; Goodin, D (Lancet Neurol, 2014)
et al.